FIELD: pharmaceuticals.
SUBSTANCE: present invention refers to compounds of formula (II) and its pharmaceutically acceptable salts, where values R1-R7, A, X, Y are specified in the patent claim. Also disclosed are pharmaceutical compositions containing compounds of formula (II), which inhibit Factor XIa or kallikrein, and methods of using said compounds and compositions.
EFFECT: disclosed are therapeutic compounds and compositions.
38 cl, 10 dwg, 3 tbl, 27 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC COMPOUNDS AND COMPOSITIONS | 2019 |
|
RU2817800C2 |
| BETA-LACTAMASE INHIBITORS | 2013 |
|
RU2654692C2 |
| SUBSTITUTED TRICYCLIC COMPOUNDS AND METHOD OF APPLICATION | 2016 |
|
RU2744766C2 |
| INHIBITION OF CREB-BINDING PROTEIN (CBP) | 2019 |
|
RU2803290C2 |
| METHYLHYDROFUMARATE PRODRUGS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS FOR USING | 2009 |
|
RU2554347C2 |
| BETA-LACTAMASE INHIBITORS AND THEIR USE | 2018 |
|
RU2815314C2 |
| SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE DERIVATIVES OF PYRIMIDINES, COMPOSITIONS THEREOF AND METHODS OF TREATING USE THEREOF | 2012 |
|
RU2697712C2 |
| SUBSTITUTED CHROMANS | 2015 |
|
RU2718060C2 |
| SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | 2011 |
|
RU2606514C2 |
| 3-CARBONYLAMINO-5-CYCLOPENTYL-1H-PYRAZOLE COMPOUNDS WITH CDK2 INHIBITOR ACTIVITY | 2020 |
|
RU2797889C2 |
